FDA-cleared profile

IRISeg

Intuitive Surgical, Inc. · Radiological images; modality varies or is not specified in FDA list · FDA-cleared (510(k))

Authorized purpose: IRISeg accepts MR or contrast-enhanced CT images for manual and machine-learning image analysis and segmentation and produces visual three-dimensional models for preoperative planning or intraoperative display; output is non-diagnostic and requires clinician decisions.

Clinical role
Medical-image processing, measurement, quantification, visualization, and reporting support.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Kidneys and other patient-specific surgical anatomy
Key limitation
Keep in mind: Outputs supplement accepted interpretation or planning methods and require review against source images; supported modality, anatomy, protocol, patient population, and version limits apply.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: IRISeg accepts MR or contrast-enhanced CT images for manual and machine-learning image analysis and segmentation and produces visual three-dimensional models for preoperative planning or intraoperative display; output is non-diagnostic and requires clinician decisions.
  • Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Kidneys and other patient-specific surgical anatomy Input: Supported DICOM images, study metadata, and release-specific user inputs.
  • Who uses it?Intended users: Qualified imaging professionals and physicians trained for the represented anatomy and workflow.
  • What does the software produce?Output: Measurements, segmentations, visualizations, calculations, models, and reports for professional review.
  • What is its most important limitation?Key limitation: Outputs supplement accepted interpretation or planning methods and require review against source images; supported modality, anatomy, protocol, patient population, and version limits apply.

Clinical takeaway. Clinical role: IRISeg accepts MR or contrast-enhanced CT images for manual and machine-learning image analysis and segmentation and produces visual three-dimensional models for preoperative planning or intraoperative display; output is non-diagnostic and requires clinician decisions.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA decision material describes DICOM MR and contrast-enhanced CT input, manual and machine-learning segmentation, kidney CT use for adults with axial slices no thicker than 3 mm, and non-diagnostic rendered output. MR use is manual where the exact package says so.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
IRISeg accepts MR or contrast-enhanced CT images for manual and machine-learning image analysis and segmentation and produces visual three-dimensional models for preoperative planning or intraoperative display; output is non-diagnostic and requires clinician decisions.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Medical-image processing, measurement, quantification, visualization, and reporting support.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Supported DICOM images, study metadata, and release-specific user inputs.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Measurements, segmentations, visualizations, calculations, models, and reports for professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Hospital or outpatient imaging analysis, reporting, or surgical-planning environments.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified imaging professionals and physicians trained for the represented anatomy and workflow.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Outputs supplement accepted interpretation or planning methods and require review against source images; supported modality, anatomy, protocol, patient population, and version limits apply.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA decision material describes DICOM MR and contrast-enhanced CT input, manual and machine-learning segmentation, kidney CT use for adults with axial slices no thicker than 3 mm, and non-diagnostic rendered output. MR use is manual where the exact package says so.
  • Exact FDA submission
  • Checked 2026-09-04

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA decision material describes DICOM MR and contrast-enhanced CT input, manual and machine-learning segmentation, kidney CT use for adults with axial slices no thicker than 3 mm, and non-diagnostic rendered output. MR use is manual where the exact package says so.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if one is later verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if one is later verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K251763 FDA evidence package for IRISeg

  • DesignFDA software substantial-equivalence decision with image import, segmentation, rendering, usability, and workflow verification
  • PopulationAdult contrast-enhanced axial kidney CT cases within the labeled slice-thickness limit plus labeled manual MR and surgical-planning workflows
  • Scopeexact submission
  • Tested versionIRISeg configuration described in K251763
  • IndependenceSponsor or vendor study

K251763

Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K251763 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Supported DICOM images, study metadata, and release-specific user inputs.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K251763: IRISeg

  2. Routing

    Source context, not route validation: The exact FDA package describes IRISeg receiving DICOM compliant MR or contrast-enhanced CT images, loading DICOM imaging files and NIfTI segmentation label files from an accessible storage location, and generating an output file used to render virtual segmented 3D models. Interface versions and local compatibility require confirmation.

    Scope: Exact FDA submission. Packet wording: "IRISeg is intended for use as a software application that receives DICOM compliant MR or contrast-enhanced CT images" … "IRISeg can open and load CT or MR imaging files in DICOM (Digital Imaging and Communications in Medicine) format, and segmentation label files in NIfTI (Neuroimaging Informatics Technology Initiative) format from an accessible storage location.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-11-14 · FDA 510(k) decision material K251763: IRISeg

  3. AI processing

    Source context, not route validation: The exact FDA package describes IRISeg as a segmentation software application running on a general-purpose computer in an office setting, with general-purpose computer host hardware. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "User interface / Graphical user interface design. Same Environment Office setting (Segmentation Software Application running on a general-purpose computer)" … "Host Hardware General-purpose computer Same Compatibility hardware". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA 510(k) decision material K251763: IRISeg

  4. Returned objects

    Source context, not route validation: Measurements, segmentations, visualizations, calculations, models, and reports for professional review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K251763: IRISeg

  5. Viewer/worklist/report

    Unresolved route: Measurements, segmentations, visualizations, calculations, models, and reports for professional review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K251763: IRISeg

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes IRISeg as a segmentation software application running on a general-purpose computer in an office setting, with general-purpose computer host hardware. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "User interface / Graphical user interface design. Same Environment Office setting (Segmentation Software Application running on a general-purpose computer)" … "Host Hardware General-purpose computer Same Compatibility hardware". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact FDA package describes IRISeg receiving DICOM compliant MR or contrast-enhanced CT images, loading DICOM imaging files and NIfTI segmentation label files from an accessible storage location, and generating an output file used to render virtual segmented 3D models. Interface versions and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "IRISeg is intended for use as a software application that receives DICOM compliant MR or contrast-enhanced CT images" … "IRISeg can open and load CT or MR imaging files in DICOM (Digital Imaging and Communications in Medicine) format, and segmentation label files in NIfTI (Neuroimaging Informatics Technology Initiative) format from an accessible storage location.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Security
Intuitive's product security program page describes a coordinated vulnerability disclosure program scoped to its medical devices, supporting software, web services, and mobile applications (reporting to product.security@intusurg.com with PGP), published security advisories with product impact assessments, and a post-market cybersecurity vulnerability monitoring program covering products including da Vinci, Ion, and digital services.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement. Applicant name variants ('Intuitive Surgical Inc.', 'Intuitive Surgical, Inc.') are the identical distinctive name. Exact-release scope is not established.

Training
Only qualified imaging professionals and physicians trained for the represented anatomy and workflow should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Outputs supplement accepted interpretation or planning methods and require review against source images; supported modality, anatomy, protocol, patient population, and version limits apply.
  • Exact FDA submission
  • Checked 2026-09-04

No current vendor source was promoted for K251763; exact-release facts remain anchored to the FDA decision material.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K251763 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Exact public integration details remain incomplete; establish and test the supported input, output, identity, routing, archive, and downtime contract locally.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. No current vendor source was promoted for this submission.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Outputs supplement accepted interpretation or planning methods and require review against source images; supported modality, anatomy, protocol, patient population, and version limits apply.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Outputs supplement accepted interpretation or planning methods and require review against source images; supported modality, anatomy, protocol, patient population, and version limits apply.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. No current vendor source was promoted for this submission.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K251763
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiological images; modality varies or is not specified in FDA list
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Kidneys and other patient-specific surgical anatomy
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-12-16
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-20Last searched
27Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K251763: IRISeg

    U.S. Food and Drug Administration - Published 2025-12-16 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Intuitive: Product Security / Coordinated Vulnerability Program

    Intuitive Surgical - Accessed 2026-10-27

    Scope: security

Research history

  1. K251763 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253969

ADAS 3D

Adas3D Medical S.L.

Authorized purpose: ADAS 3D supports visualization and analysis of MR and CT images of the heart for individual patients with cardiovascular disease, including patients with myocardial scar from ischemic or non-ischemic heart disease. Qualified professionals may use it for cardiac calculation, quantification, visualization, pre-planning, and electrophysiology procedures; produced data support clinical decision-making and must not be used as irrefutable medical advice or for radiotherapy planning, dose calculation, or treatment delivery.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Heart; myocardial scar and cardiac structures
Decision
2026-06-29
FDA-cleared K260316

CMN Capillary Function with Oncology Virtual Expert

Cercare Medical A/S

Authorized purpose: Cercare Neurosuite with Capillary Function and Oncology Virtual Expert processes CT or MR information to provide perfusion, tissue-blood-volume, diffusion, labeling, and quantification support for adult brain glioma workflows.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain
Decision
2026-06-22
FDA-cleared K261713

Synapse PACS (7.6.0)

FUJIFILM Healthcare Americas Corporation

Synapse PACS 7.6.0 provides medical-image management and processing, including measurements, regional segmentation, clinical calculations, structured reports, comparison, fusion, and volume rendering to aid reading, interpretation, reporting, and treatment planning.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
N/A
Decision
2026-06-18
FDA-cleared K252563

Neurophet SCALE PET

Neurophet., Inc.

Authorized purpose: Brain MRI/PET registration, segmentation and quantitative PET assessment

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain
Decision
2026-05-15

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history